Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...

Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of ...

Pfizer (PFE) announced results from the Phase 3 TALAPRO-2 study of TALZENNA, an oral poly ADP-ribose polymerase inhibitor, in combination with ...

US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $17.4 billion, has announced results from its Phase 3 TALAPRO-2 study which show that a combination of ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral ...